International Stem Cell Corporation to Present at the 4th Annual LD MICRO Growth Conference on December 8th

By Dr. Matthew Watson

International Stem Cell Corporation (OTCBB:ISCO) today announced that Co-Chairman Ken Aldrich and President and Chief Operating Officer Kurt May will be presenting at the 4th Annual LD MICRO Growth Conference in Los Angeles on Thursday, December 8, 2011 at 2:30 p.m. Pacific. The conference is being held at the Luxe Sunset Boulevard Hotel.

LD Micro founder Chris Lahiji stated, "We are excited to host over 100 companies for the first time in our history. What makes us especially proud, however, are all the interesting companies from our own backyard in Southern California, such as International Stem Cell, that are presenting this year."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com
or
LHA
Don Markley
310-691-7100
dmarkley@lhai.com

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss